GleamWall
中文EN

COAG Hemab Therapeutics Holdings, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 2114044 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets3.0%
Debt / equity0.00x
Current ratio33.86x
Interest coverage—

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q32025-09-302025Q22025-06-302025Q12025-03-31
Income statement
Revenue——————
R&D expense$24.64M$20.34M$19.46M$14.55M$12.87M$14.10M
SG&A expense$5.12M$5.74M$4.15M$2.50M$3.18M$2.46M
Operating income-$29.76M-$26.08M-$23.61M-$17.05M-$16.06M-$16.56M
Pretax income-$26.61M-$24.05M-$22.68M-$16.97M-$12.21M-$15.50M
Income tax$693,000$97,000$12,000$98,000$4,000-$190,000
Net income-$27.30M-$24.15M-$22.69M-$17.07M-$12.21M-$15.31M
EBITDA-$29.68M-$26.00M-$23.54M-$16.98M-$15.98M-$16.48M
EPS (basic)-0.58-0.80-23.98-18.04-12.91-16.18
EPS (diluted)-0.58-0.80-23.98-18.04-12.91-16.18
Weighted avg. shares (diluted)46.71M30.11M946,000946,000946,000946,000
Balance sheet
Cash & equivalents$239.15M$237.37M$49.86M———
Short-term investments$191.09M$220.09M$113.67M———
Current assets$438.16M$464.00M$169.43M———
PP&E, net$555,000$596,000$648,000———
Total assets$442.71M$467.78M$175.26M———
Current liabilities$12.94M$12.94M$13.19M———
Total liabilities$13.44M$13.51M$13.71M———
Shareholders' equity$429.27M$454.27M-$198.62M-$158.00M-$141.47M-$129.15M
Cash flow statement
Operating cash flow-$28.29M-$22.64M-$21.58M-$16.39M-$15.33M-$13.03M
Capital expenditure$34,000$23,000$112,000$0$0$16,000
Free cash flow-$28.32M-$22.66M-$21.70M-$16.39M-$15.33M-$13.05M
Investing cash flow$30.10M-$107.44M-$15.85M$0$21.50M-$5.99M
Financing cash flow$47,000$317.58M-$460,000-$30,000-$30,000-$29,000
Depreciation & amortization$75,000$75,000$73,000$76,000$77,000$75,000

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.